Debbie Rigby rounds up the latest in research news
Benefits and harms of intensive glycemic control in patients with type 2 diabetes
The body of evidence shows no meaningful benefit of intensive (compared with moderate) glycemic control for microvascular and macrovascular outcomes important to patients, with the exception of reduced rates of non-fatal myocardial infarction. Intensive glycemic control does, however, increase the risk of severe hypoglycemia and incurs additional burden by way of polypharmacy, side effects, and cost. The authors conclude that patient centered care to people with type 2 diabetes requires a paradigm shift and departure from the predominantly glucocentric view of diabetes management.
BMJ 2019;367:l5887.
Development of consumer information leaflets for deprescribing in older hospital inpatients
Understandable and easy-to-use consumer information leaflets were developed and tested by consumers and health professionals. At least 80% of consumers correctly found and understood the deprescribing information in the leaflets. The researchers suggest feasibility and utility of these leaflets to support deprescribing at transitions of care should be explored in clinical practice.
BMJ Open 2019;9:e033303.
Continuous PPI therapy was associated with an increased risk of developing AGE during periods of highest circulation of enteric viruses in this French cohort study. These findings support the hypothesis that PPI use is associated with an increased risk of enteric viral infections.
JAMA Netw Open. 2019;2(11):e1916205.
In this network meta-analysis of RCTs of soluble fibre, antispasmodic drugs, peppermint oil, and gut–brain neuromodulators for IBS, peppermint oil was ranked first for efficacy of global symptoms, and tricyclic antidepressants were ranked first for efficacy when abdominal pain was used as the outcome measure.
Lancet Gastroenterology & Hepatology, first published 16 December 2019.
No Comment